Enanta Pharmaceuticals (ENTA) Cash & Equivalents Growth (1y) (2013 - 2026)
Enanta Pharmaceuticals (ENTA) Cash & Equivalents Growth (1y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | 15.53% |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 90.42% |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 17.50% |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | -4.13% |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | - |
| 10 | Enanta Pharmaceuticals | 369.97 Mn | 206.20 Mn | - | -41.99% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -41.99% |
| Dec 31, 2025 | -55.62% |
| Sep 30, 2025 | -13.25% |
| Jun 30, 2025 | 25.26% |
| Mar 31, 2025 | -5.24% |
| Dec 31, 2024 | 111.23% |
| Sep 30, 2024 | -56.40% |
| Jun 30, 2024 | -62.41% |
| Mar 31, 2024 | -13.17% |
| Dec 31, 2023 | -5.42% |
| Sep 30, 2023 | 94.09% |
| Jun 30, 2023 | 235.52% |
| Mar 31, 2023 | 78.53% |
| Dec 31, 2022 | -57.38% |
| Sep 30, 2022 | -23.10% |
| Jun 30, 2022 | 516.54% |
| Mar 31, 2022 | -46.85% |
| Dec 31, 2021 | 79.81% |
| Sep 30, 2021 | -34.34% |
| Jun 30, 2021 | -95.39% |